Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Total Non-Current Liabilities (2018 - 2025)

Plus Therapeutics (PSTV) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $7.3 million as the latest value for Q2 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $7.3 million in Q2 2025 year-over-year; TTM through Jun 2025 was $7.3 million, a N/A change, with the full-year FY2020 number at $9.1 million, down 40.11% from a year prior.
  • Total Non-Current Liabilities was $7.3 million for Q2 2025 at Plus Therapeutics, down from $10.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $10.6 million in Q1 2025 to a low of $7.3 million in Q2 2025.